Summary of Product Characteristics Updated 23-Aug-2017 | Essential Pharmaceuticals Ltd
Pancrex V Capsules 125 mg
Pancreatin BP to provide enzymatic activity per capsule not less than:
160 BP units
2950 BP units
3300 BP units
Pancrex is used to compensate for reduced intestinal enzyme activity in pancreatic deficiency states.
It is indicated for the treatment of fibrocystic disease of the pancreas (cystic fibrosis), chronic pancreatitis and pancreatic steatorrhoea following pancreatectomy. It may also be indicated following gastrectomy as an aid to digestion.
These low dose capsules may be used when small amounts of Pancrex are required, for example for neonates.
Dosage should be adjusted according to the needs of the individual patient and the amount of food consumed.
The following dosage scale provides a suitable basis for adjustment. Neonates: the contents of 1 - 2 capsules mixed with feeds.
Hypersensitivity to the active ingredient (porcine pancreatin) or any of the excipients.
It is possible that some irritation of the skin of the mouth may occur if capsules
125 mg are chewed or the contents retained in the mouth. Irritation of the anus may also occur. A barrier cream may prevent this local irritation.
Allergic/asthmatic reactions have occasionally occurred on handling the capsule contents.
If the capsule contents are mixed with liquids or feeds the resulting mixture should not be allowed to stand for more than one hour prior to use.
Pancrex should not be used in pregnancy and lactation unless clearly necessary but if required should be used in doses sufficient to provide adequate nutritional status.
Rare cases of hyperuricosuria and hyperuricaemia have been reported when extremely high doses of pancreatin have been taken.
Strictures of the ileo-caecum and large bowel, and colitis, have been reported in children with cystic fibrosis taking high doses of pancreatic enzyme supplements. To date Pancrex and Pancrex V presentations have not been implicated in the development of colonic damage. However unusual abdominal symptoms or changes in abdominal symptoms should be reviewed to exclude the possibility of colonic damage especially if the patient is taking in excess of 10,000 units/kg/day of lipase.
Reporting of suspected adverse reactions
Reporting suspected reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellocard.
Pancreatin is derived from porcine pancreas and contains the enzymes, amylase, protease and lipase. The enzymes have the same actions as pancreatic juice and when administered to patients with pancreatic insufficiency improve the ability to metabolise starches, proteins and fats.
Pancreatin hydrolyses fats to glycerol and fatty acids, changes proteins into proteases and derived substances, and converts starch into dextrins and sugars.
No relevant pre-clinical safety data has been generated.
Store at a temperature not exceeding 15°C.
Securitainer; 300 and 500 capsules.
Essential Pharmaceuticals Limited
Unit 7, Egham Business Village
Surrey TW20 8RB,
13/11/1985 / 04/11/2003
7 Egham Business Village, Crabtree Road, Egham, Surrey, TW20 8RB, UK
+44 (0) 1784 471 776
+44 (0) 1784 477 167
+44 (0)1784 477 167